The OzemPIC and Wegov boxes are seen by Novo Nordisk in a pharmacy.
Holly Adams Reuters
The United States has long been shortened Novo NordskWegovy oral weight loss injection solution After more than two years, the Food and Drug Administration said on Friday.
The FDA decision will threaten the ability of pharmacies to make publications much cheaper than the injection during the next few months. Several patients have relied on unique versions of Wegovy and OzemPIC because composite pharmacies are allowed to make versions of brands with non -display.
Novo Nordsk shares rose about 5 % on Friday. Meanwhile, contributed To shake and breatheAA Eleehealth, which provides Wegovy and OzemPic, decreased.
The active ingredient in both the NOVO Nordisk drugs, SMAGLUTIDE, was in a shortage of the United States since 2022 after the high demand. That forced Novo Nordisk and its competitor Eli Lily To invest heavily to expand the effects of their feet in manufacturing to lose weight of each of them and diabetes medications – and may pay off.
The FDA’s Food and Drug Administration (FDA) has decided that the ability of the Novo Nordisk to injection to inject gruesome can now meet the current and expected demand in the United States. Pharmacies.
“We are pleased that the FDA has announced that providing the only only drugs approved by the Food and Drug Administration (FDA),” Dave Moore, CEO of American Operations and World Business Development said in a statement.
He added that “no one should have to bargain with his health due to wrong information and access to false or illegal fatal drugs that pose great safety risks to patients.”
The Food and Drug Administration announces a few months after the agency Declare The shortage of TEPBOUND and Mounjaro Diabetes – has ended.
Food and Drug Administration (FDA) on Friday can put novo Nordisk better to compete with Eli Lilly in the prosperous weight loss drugs market, which some analysts say the value of more than $ 150 billion annually after 2030.
A threat to complex medicines
The agency’s decision, based on a comprehensive analysis, represents the end of the period in which the compound pharmacies can distribute, distribute or distribute not approved versions of the pillar without facing repercussions on violations related to the state of lack of treatment.
The agency said that the guaranteed pharmacies should stop making vehicle versions of the semolina in the next sixty to 90 days, depending on the type of facility. The transition period is likely to give time to switching to drug branded versions.
But in compliance with the rules of food and drugs management, vehicles can still create alternative versions of medications if they adjust the doses, add other components, or change the method of providing treatment to meet the needs of a specific patient.
Some patients rely on complex versions because they do not have insurance coverage for Novo Nordisk and they cannot bear the signs of their huge prices of about $ 1,000 a month. Although OzemPIC is covered with most health plans, weight loss medications such as Wegov are not currently covered by Medicare and OONE Insurance.
https://image.cnbcfm.com/api/v1/image/108002261-17202050682024-07-02t123005z_1215430252_rc2kh6a0fjbk_rtrmadp_0_health-obesity-biden.jpeg?v=1720205117&w=1920&h=1080
Source link